Shifting Sands: What a Vaccine Advisory Committee Member’s Removal Signals The recent, unexpected removal of Veronica McNally, an attorney and director of trial advocacy at Michigan State University, from the Advisory Commission on Childhood Vaccinations (ACCV) has sent ripples through the world of vaccine safety and injury compensation. While the Department of Health and Human … Read more
The Looming Medicaid Cliff and the Future of Healthcare Finance The scene at a San Francisco yacht club – a gathering of healthcare titans alongside figures like Mehmet Oz – underscores a critical, and increasingly anxious, moment for the industry. While the setting might suggest celebration, the underlying reality is a looming financial reckoning driven … Read more
The Rise of ‘Medical Super-Intelligence’: How AI is Poised to Revolutionize Healthcare The healthcare landscape is undergoing a seismic shift, driven by advancements in artificial intelligence. OpenEvidence, a company rapidly gaining traction in the medical field, exemplifies this transformation. Their reported growth – from 2.6 million clinical evidence chatbot queries in 2024 to a staggering … Read more
The AI-Powered Doctor is In: How Generative AI is Reshaping Healthcare The healthcare landscape is undergoing a seismic shift, driven by the rapid advancement and adoption of artificial intelligence. No longer a futuristic fantasy, AI – particularly generative AI – is moving from research labs into clinics, hospitals, and even directly into the hands of … Read more
UnitedHealth’s Coding Practices: A Glimpse into the Future of Medicare Advantage A recent Senate Judiciary Committee report has thrown a spotlight on UnitedHealth Group’s aggressive tactics in maximizing payments within the Medicare Advantage program. The core issue? How patients are “coded” – the diagnoses listed on their medical records – directly impacts how much money … Read more
The FDA’s Shifting Stance on Expedited Drug Approval: A Biotech Turning Point? The recent snag between Stoke Therapeutics and the FDA regarding accelerated approval for zorevunersen, a potential treatment for Dravet syndrome, isn’t an isolated incident. It signals a potentially significant shift in how the agency evaluates novel therapies, particularly those utilizing innovative approaches like … Read more
Alnylam’s Bold Vision: Gene Silencing and the Future of Biotech Alnylam, a pioneer in RNA interference (RNAi) therapeutics, recently unveiled its “Alnylam 2030” plan, signaling a continued commitment to innovation and ambitious growth. While recent quarterly sales of its flagship drug, Amvuttra, slightly missed expectations, the company’s long-term outlook remains remarkably optimistic. This isn’t just … Read more
Beyond JPM Week: The Evolving Biotech Landscape The future of biotech extends far beyond the annual JPM Healthcare Conference.The annual JPM Healthcare Conference in San Francisco is a pivotal moment for the biopharmaceutical industry, a concentrated burst of deal-making and networking. But as Adam Feuerstein rightly points out, the engine of biotech innovation doesn’t pause … Read more
ACA Subsidies Extended: What Does the Future Hold for Healthcare Affordability? The House’s recent vote to extend enhanced Affordable Care Act (ACA) premium subsidies for another three years is a significant, though potentially temporary, reprieve for millions of Americans. But it’s also a stark signal: healthcare affordability is rapidly becoming a defining political issue, even … Read more
NIH Funding Fight: A Turning Point for University Research? A recent federal appeals court ruling has delivered a significant win to universities and academic medical centers, halting the National Institutes of Health (NIH) from implementing cuts to research overhead funding. This decision isn’t just about billions of dollars; it signals a potential shift in how … Read more